Comparative review of the effects of inhaled beclomethasone dipropionate and budesonide on bone  by D'Souza, M.
RESPIRATORY MEDICINE (1998) 92 (SUPPLEMENT B), 24-36 
Comparative review of the effects of inhaled 
beclomethasone dipropionate and budesonide 
on bone 
M. D’SOUZA 
Royal Brompton National Heart & Lung Institute, The Unit of General Practice, Kingston Upon Thames, Surrey, U.K. 
Introduction 
The role of inflammation in asthma is now well recog- 
nized, and corticosteroids are being used increasingly in 
its treatment. However, frequent high-dose courses of 
oral steroids result in many side-effects including loss of 
bone mass, which can eventually lead to osteoporosis 
and fractures (1). Several mechanisms may be involved 
in this process (2-5) (Fig. 1). Inhaled steroids have a 
wider therapeutic margin than oral steroids as a result 
of their high topical: systemic potency ratio, low 
bioavailability and high systemic clearance (2). It is now 
recommended that regular inhaled steroids are started 
earlier in the course of asthma and that high doses are 
used initially to attain control of the disease (6), but 
there is still some concern that the amount absorbed 
might be sufficient to cause systemic side-effects. 
The effect of high-dose inhaled corticosteroids on 
bone has been investigated in healthy adult volunteers 
and asthma patients of various ages. This review sum- 
marizes the data on beclomethasone dipropionate 
(BDP) and budesonide, the two most widely used 
inhaled steroids in the U.K. 
Experience in Adults 
HEALTHY VOLUNTEERS 
Non-comparative studies 
Studies in healthy adult volunteers have investigated 
the effects of high-dose inhaled corticosteroids on 
bone turnover using serum and urinary levels of 
various markers of bone metabolism, including 
hormones, enzymes and bone constituents. Non- 
comparative and placebo-controlled studies in 
Correspondence should be addressed to: M. D’Souza, 
Royal Brompton National Heart & Lung Institute, The Unit 
of General Practice, 1 Elm Road, Kingston upon Thomes, 
Surrey KT2 6HR, U.K. 
This supplement was sponsored by Glaxo Wellcome plc. 
0954-6111/98/928024+13 $12.00/O 
subjects receiving high-dose BDP or budesonide for 
periods of 1 week to 1 month have generally found a 
reduction in serum osteocalcin levels, which has been 
interpreted as indicating reduced bone formation by 
osteoblasts (Table 1) (7-15). This reduction is 
reversible; levels have been shown to return to base- 
line within 1 week of ceasing treatment with BDP 
2000 pg daily (13). A placebo-controlled, cross-over 
study in 16 volunteers receiving BDP 400-2000 pg 
daily for 10 days attempted to define the threshold 
dose at which bone is affected (14). A dose-dependent 
fall in serum osteocalcin levels was observed with 
BDP doses up to 1400 pg daily, at which the response 
reached a plateau. A study comparing oral pred- 
nisolone 15 mg daily with inhaled BDP 1000 pg daily 
reported a decrease in serum osteocalcin with both 
treatments, but the decrease was greater in volunteers 
receiving prednisolone (10). In contrast, Peretz and 
Bourboux (12) detected no significant changes in 
serum osteocalcin, or any of the biochemical markers 
measured, in volunteers receiving inhaled BDP 1000 pg 
daily for 1 week. 
Toogood et al. (15) found that inhaled budesonide 
1200 or 2400 pg daily for 1 month reduced serum 
osteocalcin levels but did not alter urinary calcium or 
hydroxyproline output. Two further randomized, 
double-blind studies comparing the effects of inhaled 
budesonide and oral prednisolone reported similar 
results. In the first study (8,9), increasing doses of 
budesonide or prednisolone over a period of 3 weeks 
caused significant reductions in serum osteocalcin lev- 
els, but other serum and urinary markers remained 
unchanged. In the second study (7), 40 subjects 
received either high- or low-dose oral prednisolone 
or inhaled budesonide for 2 weeks while 10 control 
subjects received placebo. Serum osteocalcin levels 
were significantly reduced from baseline in a dose- 
dependent manner during the first week of steroid 
therapy in both treatment arms, with there being no 
significant difference between treatments. No effect on 
urinary calcium or hydroxyproline was seen during 
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FIG. 1. Possible mechanisms by which oral steroids 
may cause bone loss. 
budesonide treatment, in contrast to increases in these 
parameters with high-dose prednisolone. 
Nadeau et al. (11) found no effects of budesonide 
(at doses up to 2400 l.rg daily for 14 days) on intestinal 
calcium absorption, serum calcium, phosphate and 
PTH levels. 
Comparative studies 
Four studies have directly compared the effects of BDP 
and budesonide on bone metabolism in healthy volun- 
teers, and these are summarized in Table 2 (1619). 
Brown et al. (17) measured plasma osteocalcin follow- 
ing inhalation of BDP or budesonide 2000 pg daily 
from metered dose inhalers (MDIs) with or without a 
spacer on six separate study days. There were no signif- 
icant changes in plasma osteocalcin following budes- 
onide, with or without a spacer; BDP reduced plasma 
osteocalcin at 24 h when inhaled without a spacer, but 
not when a spacer was used. In contrast, in another 
study BDP 2000 lrg daily for 4 weeks via an MD1 plus 
spacer produced a statistically significant increase in 
the urinary hydroxyproline:creatinine ratio and a fall in 
serum alkaline phosphatase (16). However, values for 
both of these parameters remained within the normal 
ranges during treatment, and hence the clinical signifi- 
cance of these changes is uncertain. In addition, this 
study also found that in healthy volunteers inhaling 
budesonide 1800 pg daily through a spacer for 4 weeks 
there were no significant changes for any of these 
markers (16). 
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Jennings et al. (18) compared budesonide and 
BDP, both at doses of 800 pg daily increasing to 
2500 pg daily, over 4 weeks. Serum osteocalcin and 
alkaline phosphatase levels fell during both treat- 
ments, but the reduction was significantly greater 
for those receiving BDP. The increase in urinary 
hydroxyproline:creatinine ratio observed following 
steroid treatment was also significantly greater with 
BDP Both drugs produced an increase in serum 
phosphate, but serum and urinary calcium remained 
stable. In a randomized, double-blind comparison of 
BDP 1000 or 2000 ng daily and budesonide 800 or 
1600 l.rg daily, subjects received each treatment for 
1 week at the lower dose and then 1 week at the 
higher dose (19). At the lower doses, neither drug had 
an appreciable effect on serum osteocalcin. However, 
BDP 2000 l.rg daily produced a significant reduction 
in serum osteocalcin levels, which was not observed 
after budesonide 1600 pg daily. 
The results of all volunteer studies in healthy 
volunteers indicate that both high-dose inhaled BDP 
and budesonide can impair bone metabolism but 
that inhaled steroids, even when used at very high 
doses, have considerably less effect than oral 
steroids. In addition, budesonide appears to have 
less effect than BDP on bone turnover indices (par- 
ticularly osteocalcin) at clinically relevant doses. 
However, these results have to be interpreted with 
caution as the response to steroids in healthy sub- 
jects may be different from that in asthma patients, 
and asthma itself may have an effect on bone meta- 
bolism. Effects on bone in asthma patients are there- 
fore difficult to predict from volunteer studies. In 
addition, all these studies used small subject groups 
that lacked statistical power, while several were 
uncontrolled (10,11,13) and/or included doses higher 
than those used in clinical practice (7-9,11,15). One 
study included patients in both treatment arms 
without a formal cross-over design, which might 
have confounded the results (16). Furthermore, all 
of these studies examined the effects of the two 
steroids on bone metabolism for periods of less than 
1 month. Such short-term effects may be at least 
partially compensated over time and do not necessarily 
translate into osteoporosis in the long term (20). A 
further problem was that no absolute baseline values 
were given in some studies (14,lS) and it is difficult 
to assess, therefore, whether the statistically signifi- 
cant changes found are of clinical relevance. 
ASTHMA PATIENTS 
Studies in asthma patients have investigated the effects 
of high-dose inhaled corticosteroids on bone density 
and bone turnover (Tables 3 and 4) (21-29). 
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Non-comparative studies 
Kerstjens et al. (23) retrospectively analysed samples 
from a randomized, double-blind, parallel-group 
study in which patients on bronchodilators received 
additional BDP (800 pg daily), ipratropium bromide 
or placebo. No significant differences in levels of 
PICP, a marker of bone formation, or ICTP, an 
indicator of resorption, were detected between serum 
samples collected before and after 2.5 yr of treatment 
in the BDP-treated group. 
Boulet et al. (21) compared the effects of high-dose 
BDP or budesonide (2800 ug daily) taken for at least 
18 months with those of low doses (~500 ug daily) in 
matched groups of patients with low oral steroid usage 
over the previous 2 yr. Serum osteocalcin was lower 
and urinary phosphate higher in patients using high- 
dose inhaled steroids, but there were no significant dif- 
ferences in the bone density of the lumbar spine and 
hip or markers of bone metabolism between low- and 
high-dose groups. In addition, there were no signifi- 
cant differences in bone density or osteocalcin levels 
between patients receiving BDP and budesonide, 
although this study was not designed to compare dif- 
ferences between the individual agents. A further study 
in patients who had taken a mean dose of 1323 p.g 
daily of BDP or budesonide for a median of 2 yr also 
found significantly reduced osteocalcin levels com- 
pared with age- and sex-matched patients receiving 
bronchodilators only (22). The mean density of the 
femoral neck of these patients was significantly 
reduced in the steroid-treated group and was below the 
normal clinical range; however, there was no signifi- 
cant difference in this parameter between steroid- 
treated patients and those receiving bronchodilators 
alone, possibly suggesting it might be disease related. 
Mean bone density in the lumbar spine and Ward’s 
triangle of the femur remained within the expected 
clinical range in both treatment groups. 
Four studies have reported the effects of oral and 
inhaled steroids on bone turnover and density. Luengo 
et al. (24) observed no differences in calcium absorp- 
tion or PTH serum levels between steroid-dependent 
patients treated with inhaled BDP (400-1600 ug daily) 
or oral steroids for a mean of 6.7 yr, and age- and sex- 
matched healthy volunteers. In a second study, Luengo 
et al. (25) compared changes in bone mass over 2 yr in 
21 patients on oral steroids (mean 12 mg daily), 21 on 
inhaled BDP (100-900 ug dailyband 875 control sub- 
jects. The rate of bone loss for patients on oral steroids 
was higher than in control subjects, whereas there was 
no difference in this parameter between those on 
inhaled steroids and controls. Wolff et al. (28) reported 
a dose-response relationship between cumulative oral 
steroid dose and bone loss in five patients receiving 
an average of 12.5 mg daily oral prednisolone or 
equivalent for l-10 yr, but there was no evidence of 
reduced bone density in five patients who had received 
inhaled steroids (average dose 326 ug daily BDP or 
equivalent) for a similar period. Packe et al. (26) 
compared 17 patients with mild asthma who were 
steroid naive, 20 on inhaled BDP (1000-2000 ug daily 
for >l yr) and 20 on inhaled steroids plus continuous 
low-dose oral steroids. Bone,densities were significantly 
reduced with both oral and inhaled therapy, but the 
levels of markers of bone turnover in serum and urine 
remained unchanged. 
Packe et al. (26) measured trabecular VBD in patients 
who had received inhaled budesonide (median dose 
800 ug daily) for >l yr. VBD values for these patients 
were compared, retrospectively, with those from 
patients of an earlier study (26) who had used BDP 
(median dosage 1000 ug daily) for >l yr and patients 
who were steroid naive. Budesonide and BDP patients 
were matched for age, level of activity and asthma 
severity. VBD was significantly lower in both the budes- 
onide and the BDP groups than in untreated patients. 
There was no significant difference in VBD between the 
BDP and budesonide patients, even when the budes- 
onide results were adjusted to take into account the sig- 
nificant difference in dosage. Moreover, no significant 
differences in serum or urinary markers of bone 
turnover were observed between the three groups. 
Comparative studies 
In a pilot study to validate two novel markers of bone 
turnover, Kerstjens et al. (23) measured serum alkaline 
phosphatase, osteocalcin and PICP levels as markers 
of bone formation, together with the urinary hydroxy- 
proline:creatinine ratio and serum ICTP levels as 
markers of bone resorption, in patients receiving 
budesonide or BDP 2800 ug daily. In both treatment 
groups osteocalcin levels decreased significantly while 
PICP levels and the PICP:ICTP ratio increased signif- 
icantly after 4 weeks of treatment. There were no sig- 
nificant differences in serum osteocalcin, PICP or 
ICTP between groups receiving budesonide or BDP 
Morrison et al. (29) detected no changes in the urinary 
hydroxyproline:creatinine or calcium:creatinine ratios 
or serum alkaline phosphatase in patients with chronic 
obstructive airways disease treated with BDP or 
budesonide 2000 pg daily in a placebo-controlled 
cross-over trial. However, significant reductions were 
observed in both treatment groups in the urinary 
pyridinoline:creatinine and deoxypyridinoline:creati- 
nine ratios, indicating reduced bone resorption. Serum 
osteocalcin levels fell by 26% with budesonide and 
18% with BDP but, because a significant period effect 
was apparent and baseline osteocalcin levels were 
significantly different between treatments, there is no 
significant difference between the two steroids. 
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These studies in asthma patients generally con- 
firmed the effects of inhaled corticosteroids on 
markers of bone turnover observed in healthy volun- 
teers. However, bone density studies, although 
conducted using accurate, modern techniques, show 
conflicting results. While these studies were conducted 
over longer periods of time, in larger groups of 
patients and at more clinically relevant doses than the 
volunteer studies, many were retrospective or cross- 
sectional and could not evaluate progressive changes 
over time. In addition, most patients had previously 
taken oral corticosteroids, and the possible impact of 
this on bone could not be assessed. 
POST-MENOPAUSAL WOMEN 
Loss of bone mass occurs as a natural consequence of 
ageing. It may begin as early as the third decade in 
women and accelerates after the menopause when the 
protective effect of oestrogen is lost (30,31). Hence, 
any additional bone loss caused by corticosteroid 
treatment is an obvious cause for concern in this group 
of patients already at increased risk of osteoporosis. 
Puolijoki et al. (32) assessed bone metabolism in 
nine post-menopausal women with asthma receiving 
BDP 200, 1000 or 2000 pg daily via a spacer for 
3 weeks. Serum osteocalcin was significantly reduced 
throughout the 9-week follow-up period, but there 
were no significant alterations in other serum or urinary 
markers of bone turnover (Table 5). Stead et al. (32) 
investigated bone m ineral density in a cross-sectional 
study in 11 asthmatic women aged 36-73 years, most 
of whom were post-menopausal. Ten had received 
BDP or budesonide 750-2000 pg daily for I-IO yr, 
and one had received both drugs. Lumbar spine bone 
density was reduced by 13% in these patients com- 
pared with healthy age-matched controls, but there 
was no evidence of active, rapid bone loss (Table 5). It 
is possible that previous oral corticosteroid therapy 
may have played a role in reducing bone mass in these 
patients. 
Experience in Children 
The impact of inhaled corticosteroids on bone forma- 
tion is a particularly important aspect of treatment in 
children since they are actively growing. Studies in the 
patient population are summarized in Table 5 (34-38). 
Two studies reported no significant differences in 
bone m ineralization or density between asthmatic chil- 
dren receiving BDP 300-800 pg daily for 6-25 months 
and age-matched controls (34,37); serum osteocalcin 
was also unaffected (37). Priftis et al. (38) studied the 
effect of long-term use of inhaled BDP on biochemical 
markers of bone turnover and bone m ineral content in 
33 asthmatic children (median age 10 years) treated 
with BDP 180-790 pg m-2 day-l for 6-48 (mean 11.5) 
months. A dose-dependent, but not time-dependent, 
decrease in serum osteocalcin was demonstrated and 
the urinary calcium:creatinine ratio was elevated. No 
effects on markers of bone resorption were observed, 
but there was a reduction in bone m ineralization that 
was independent of both dose and time. 
Doull et al. (36) found no significant differences in 
baseline or three-monthly serum osteocalcin and 
urinary hydroxyproline measurements in 94 children 
receiving either BDP 200 ug twice daily by dry powder 
inhalation or placebo for 6 months in a randomized, 
double-blind trial. In contrast, an open, cross-over 
study during which 13 pre-pubertal children received 
BDP 800 pg daily via a Diskhaler@ and budesonide 
800 pg daily via a TurbohalerB for 14 days found sig- 
nificantly reduced levels of PICP, the amino terminal 
of type III collagen, together with decreased urinary 
pyridinoline and deoxypyridinoline cross-links; this 
indicates suppression of bone and collagen turnover. 
This suppression was more apparent with BDP. 
Osteocalcin levels were not affected by either treat- 
ment (35). 
These results suggest that continuous treatment 
with BDP 1800 ug daily does not affect bone density 
in children. A reduction in bone and collagen turnover 
observed was with both budesonide and BDP at these 
doses, with the effect of budesonide being slightly less 
than that of BDP 
Considerations 
The threshold dose at which systemic side-effects 
appear with inhaled BDP in adults is believed to be 
approximately 1000 l.tg daily (39). However, results 
have varied considerably between studies, with some 
studies in adults reporting no effects on bone turnover 
indices or bone mass with BDP 11000 yg daily 
(12,19,23-25) while others found effects on osteocal- 
tin at BDP doses of < 1000 pg daily (10,14) or budes- 
onide doses of 800-1200 pg daily (7-9,15). Thus, the 
threshold dose for the effects of inhaled steroids on 
bone cannot clearly be defined. 
The difference in effects on markers of bone 
turnover may reflect the sensitivities of these indica- 
tors. Osteocalcin is a bone matrix protein that is 
released by osteoblasts and widely regarded as a sensi- 
tive marker of bone formation. However, it can also be 
released during resorption (40) and attracts osteoclasts 
(41). The clinical significance of osteocalcin suppres- 
sion remains unknown and it may be most useful when 
used in conjunction with other markers. Changes in 
levels of collagen-related proteins, such as PICP and 
ICTP, m irror those of osteocalcin (23), but collagen is 
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not specific to bone. Increased blood and/or urinary 
levels of calcium, phosphate and hydroxyproline 
indicate bone resorption, but there are concerns over 
the sensitivity and specificity of these markers (42). 
Studies relying on these measurements (11,16,24) may 
not have the sensitivity to detect small changes from 
baseline or differences between treatments. 
Short-term steroid-induced bone loss may be com- 
pensated over time by mechanisms that restore the 
equilibrium between bone formation and resorption 
but which cannot replace the deficit in bone mass. This 
might explain the reduction in bone density but nor- 
mal levels of markers of bone turnover observed in 
some studies (27). Conversely, several other studies 
(21,25,37) found that, although markers of bone 
turnover were altered after long-term use of high-dose 
inhaled steroids, bone density was not significantly 
reduced. Thus, abnormal serum or urinary marker lev- 
els do not necessarily mean later bone weakness or 
increased risk of fracture. Genetic factors, bone den- 
sity before beginning treatment, activity levels, diet 
and hormonal status are also important determinants 
of bone loss. It may, therefore, be that certain groups 
of patients are more susceptible to clinically important 
bone loss during steroid treatment than others. 
A final important consideration is inhaler design. 
Systemic absorption of inhaled corticosteroids can be 
a problem with pressurized MDIs, because the high 
velocity of particle delivery means that about 80% of 
the dose is deposited on the oropharyngeal mucosa 
(43) where it is available for uptake into the systemic 
circulation. Deposition is reduced to about lo-15% if 
a large-volume spacer is attached to the inhaler (44). 
Use of a spacer has been shown to lower the incidence 
of local steroid side-effects (4547), and it is logical 
to assume that decreased availability for systemic absor- 
ption resulting from lower oropharyngeal deposition 
would reduce any effects on bone. Using the 
Turbuhaler@ breath-actuated dry powder delivery 
system for budesonide results in reduced drug deposi- 
tion in the mouth (by approximately 60%) compared 
with the MD1 without a spacer (48). Thus, differences 
in systemic side-effects may reflect differences in 
inhaler technology. This might explain the apparent 
differences in effects on osteocalcin observed by 
Brown et al. (17) when using a MD1 with and without 
a spacer. However, inclusion of a spacer does not 
always prevent systemic effects, as noted in several 
studies (7,16). 
A dry powder inhaler for BDP, the DiskhalerB, 
has been available for some time and delivers compa- 
rable doses to the budesonide Turbuhaler@ (49). 
Comparisons of the effects of inhaled corticosteroids 
on bone using these equivalent devices would help to 
provide a clearer picture of any differences between 
BDP and budesonide. To date, only one short-term 
study of this type in children (35) has been performed. 
Finally, rinsing the mouth with water after inhalation 
can remove 80% of the oropharyngeal deposit (45). 
Careful attention to inhalation technique can thus 
help to minimize any adverse systemic effects. 
Conclusions 
Studies in healthy adult volunteers and asthma 
patients of various ages have shown that both BDP 
and budesonide can cause changes in markers of bone 
turnover, especially osteocalcin, when inhaled at high 
doses. While these changes are suggestive of bone loss, 
bone density studies in asthma patients after long- 
term treatment have produced conflicting results. 
Inhaled steroids have considerably fewer adverse 
effects on bone than oral steroids, but the threshold 
dose at which they begin to affect bone remains 
unclear. Direct comparisons suggest that budesonide 
may exert less effect on bone turnover than BDP, but 
studies with adequate controls for previous corticos- 
teroid use, asthma severity, activity levels and type of 
inhaler are required to confirm these differences. 
Prospective, long-term measurements of bone density 
are also required to establish whether changes in 
markers of bone turnover translate into an increased 
risk of osteoporosis and fractures, particularly in 
patients with increased susceptibility resulting from 
genetic factors, age or hormonal status. 
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